GlassScriptPhysician profile
Rama Reddy
NPI 1386724672
$7,695.51
in general payments reported to CMS, 2019-2025
33 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,395 · 2020: $1,372 · 2021: $1,737 · 2022: $1,614 · 2023: $796 · 2024: $582 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,012.07 | 2019-2024 | Farxiga |
| Amgen INC. | $946.38 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $924.30 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $716.37 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $608.84 | 2019-2025 | Ozempic, Rybelsus |
| Mannkind Corporation | $503.19 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $472.73 | 2019-2024 | Xifaxan, Cycloset |
| Janssen Pharmaceuticals, INC | $409.34 | 2019-2020 | |
| Abbott Laboratories | $369.96 | 2021-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $238.52 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $224.82 | 2021-2023 | |
| Insulet Corporation | $202.87 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $118.59 | 2019 | |
| Abbvie INC. | $114.31 | 2020-2024 | |
| Kowa Pharmaceuticals America, INC. | $113.95 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $105.09 | 2021-2022 | |
| Radius Health, INC. | $71.95 | 2019-2024 | Tymlos |
| Dexcom, INC. | $62.46 | 2021-2023 | Dexcom G6 Transmitter |
| Endo Pharmaceuticals INC. | $56.37 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $55.43 | 2020-2021 | |
| Medtronic, INC. | $53.76 | 2021-2022 | |
| Cequr Corporation | $51.05 | 2021-2023 | Cequr Simplicity |
| Becton, Dickinson and Company | $44.37 | 2020-2022 | |
| Ibsa Pharma INC. | $40.74 | 2021 | |
| Xeris Pharmaceuticals, INC. | $35.47 | 2022-2023 | Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $30.83 | 2023-2024 | Isturisa, Signifor Lar |
| Corcept Therapeutics | $18.55 | 2024 | Korlym |
| Valeritas, INC. | $18.55 | 2019 | |
| Pfizer INC. | $18.19 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.32 | 2023 | Strensiq |
| Amryt Pharma Holdings LTD | $14.31 | 2021 | |
| Lifescan, INC. | $13.38 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rama Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.